Pharmacoeconomic review report: Adalimumab (Humira)
Adalimumab (Humira) is an anti‐tumour necrosis factor alpha (TNF alpha), available as a syringe of 40 mg/0.8 mL solution for subcutaneous injection at a unit price of $ 40.36 per syringe. The current review of adalimumab is for the treatment of adult patients with moderately to severely active ulcer...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, April 2016
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Adalimumab (Humira) is an anti‐tumour necrosis factor alpha (TNF alpha), available as a syringe of 40 mg/0.8 mL solution for subcutaneous injection at a unit price of $ 40.36 per syringe. The current review of adalimumab is for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids, azathioprine and/or 6‐mercaptopurine (6‐MP), or who are intolerant to such therapies |
|---|---|
| Physical Description: | 1 PDF file (viii, 39 pages) illustrations |